Suggested Remit: To evaluate the benefits and costs of emapalumab within its marketing authorisation for treating primary haemophagocytic lymphohistiocytosis for national commissioning by NHS England.
Status Proposed
Process HST
ID number 1438

Project Team

Project lead Gemma Barnacle

Email enquiries


Key events during the development of the guidance:

Date Update
14 September 2018 (14:00) Scoping workshop (London)
24 July 2018 - 21 August 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance